Likewise, HA-RHAMM interaction enhanced phosphorylation of EGFR, ERK1/2, and STAT3, and these effects were blocked by gefitinib, an inhibitor of EGFR signaling, suggesting that HA-RHAMM signaling uses EGFR to promote tumor cell survival [32]. The gene discussed is EGFR; the disease is neoplasm.